2.76
0.82 (42.07%)
| Previous Close | 1.94 |
| Open | 2.00 |
| Volume | 843,663 |
| Avg. Volume (3M) | 11,128 |
| Market Cap | 31,569,746 |
| Price / Sales | 11.83 |
| Price / Book | 2.50 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2025 |
| Operating Margin (TTM) | -80.19% |
| Diluted EPS (TTM) | -1.21 |
| Quarterly Revenue Growth (YOY) | 1,996.90% |
| Total Debt/Equity (MRQ) | 22.93% |
| Current Ratio (MRQ) | 4.48 |
| Operating Cash Flow (TTM) | -12.01 M |
| Levered Free Cash Flow (TTM) | -7.67 M |
| Return on Assets (TTM) | -38.34% |
| Return on Equity (TTM) | -75.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CollPlant Biotechnologies Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.16% |
| % Held by Institutions | 12.23% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (D. Boral Capital, 335.40%) | Buy |
| Median | 11.50 (317.26%) | |
| Low | 11.00 (HC Wainwright & Co., 299.12%) | Buy |
| Average | 11.50 (317.26%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 16 Sep 2025 | 12.00 (335.40%) | Buy | 2.58 |
| 20 Aug 2025 | 12.00 (335.40%) | Buy | 1.97 | |
| HC Wainwright & Co. | 21 Aug 2025 | 11.00 (299.11%) | Buy | 2.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Sep 2025 | Announcement | CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler |
| 15 Sep 2025 | Announcement | CollPlant Expands the Distribution of its VergenixSTR Product in Europe |
| 02 Sep 2025 | Announcement | CollPlant to Present at the 2025 International Conference on Biofabrication |
| 25 Aug 2025 | Announcement | CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference |
| 20 Aug 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE |
| 05 Aug 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |